<DOC>
	<DOCNO>NCT01764633</DOCNO>
	<brief_summary>The primary hypothesis additional LDL-C lowering Evolocumab ( AMG 145 ) use addition treatment dyslipidemia well tolerated decrease risk cardiovascular death , myocardial infarction , hospitalization unstable angina , stroke , coronary revascularization subject clinically evident cardiovascular disease .</brief_summary>
	<brief_title>Further Cardiovascular Outcomes Research With PCSK9 Inhibition Subjects With Elevated Risk</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Male female ≥ 40 ≤ 85 year age History clinically evident cardiovascular disease high risk recurrent event Fasting LDLC ≥ 70 mg/dL ( ≥ 1.8 mmol/L ) ) nonHDLC ≥ 100 mg/dL ( &gt; 2.6 mmol/L ) Fasting triglyceride ≤ 400 mg/dL ( 4.5 mmol/L ) NYHA class III IV , last known leave ventricular ejection fraction &lt; 30 % Uncontrolled hypertension Uncontrolled recurrent ventricular tachycardia Untreated hyperthyroidism hypothyroidism Homozygous familial hypercholesterolemia LDL plasma apheresis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Treatment high cholesterol</keyword>
	<keyword>Lowering cholesterol</keyword>
	<keyword>Lowering high cholesterol</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>